CIK 0001678660
- Non-accelerated filer
- Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811384762
- Phone
- +1 302-467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-21 | ORBIMED ADVISORS LLC Director | Purchase | +1,689,189 | $4.44 | $7.5M | 11,808,945 |
| 2026-04-21 | ORBIMED ADVISORS LLC Director | Purchase | +1,126,126 | $4.44 | $5.0M | 1,126,126 |
| 2023-05-22 | ORBIMED ADVISORS LLC Director | Purchase | +869,565 | $5.75 | $5.0M | 10,119,756 |
| 2021-01-11 | ORBIMED ADVISORS LLC Director | Purchase · Non-Voting Common Stock | +41,700 | $60.00 | $2.5M | 5,596,886 |
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion | +8,332,779 | 9,250,191 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −3,294,743 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series A Prefered Stock | −2,196,494 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −4,418,186 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −2,945,458 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −619,850 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −413,234 | 0 | ||
| 2020-09-29 | ORBIMED ADVISORS LLC Director | Conversion · Non-Voting Common Stock | +5,555,186 | 5,555,186 | ||
| 2020-09-25 | ORBIMED ADVISORS LLC Director | Purchase | +526,300 | $19.00 | $10.0M | 526,300 |
| 2020-09-25 | ORBIMED ADVISORS LLC Director | Purchase | +710,500 | $19.00 | $13.5M | 917,412 |
| 2020-08-21 | ORBIMED ADVISORS LLC Director | Purchase · Series C Preferred Stock | +1,033,084 | 1,033,084 | ||
| 2020-03-27 | ORBIMED ADVISORS LLC Director | Purchase · Series B Preferred Stock | +3,681,822 | 7,363,644 |
Page 1 of 1 · 16 trades